Literature DB >> 32079388

18F-NaF PET/CT and Extraordinary Involvement: Non-calcific Brain Involvement in a Prostate Cancer Case

Ulku Korkmaz1, Funda Ustun1.   

Abstract

With the increase in the diagnosis of the cancer, the frequency of using imaging methods for diagnosis and for staging is also increased. Because of the complex structure of cancer and tumor behavior, the assessment methods have been updated and metabolic imaging has gained weight. The most popular of these techniques is hybrid positron emission tomography/computed tomography (PET/CT) systems. Prostate cancer is the second most common cancer in the world, is the fifth common type in cancer-related male deaths. Estimation of prognosis and treatment planning of the patients are based on the TNM classification. Bone metastasis is a prognostic factor of morbidity and mortality in prostate cancer. Sodium fluoride (NaF) PET/CT is a promising imaging modality in evaluation of skeletal system. This article will review the involvement of 18F-NaF in extra-osseous tissues in the prostate cancer and reveal the fundamental differences between 18F-NaF imaging and 18F-FDG imaging in these areas.

Entities:  

Keywords:  NaF; PET; brain; metastasis

Year:  2020        PMID: 32079388      PMCID: PMC7057725          DOI: 10.4274/mirt.galenos.2019.85547

Source DB:  PubMed          Journal:  Mol Imaging Radionucl Ther        ISSN: 2146-1414


  7 in total

1.  Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer.

Authors:  U Wissenbach; B A Niemeyer; T Fixemer; A Schneidewind; C Trost; A Cavalie; K Reus; E Meese; H Bonkhoff; V Flockerzi
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

2.  (18)F-fluoride PET for monitoring therapeutic response in Paget's disease of bone.

Authors:  Johanne Installé; Adrien Nzeusseu; Anne Bol; Geneviève Depresseux; Jean-Pierre Devogelaer; Max Lonneux
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

3.  18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin).

Authors:  Gary Cook; Chris Parker; Sue Chua; Bernadette Johnson; Anne-Kirsti Aksnes; Val J Lewington
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

4.  Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals.

Authors:  D F Worsley; B C Lentle
Journal:  J Nucl Med       Date:  1993-09       Impact factor: 10.057

Review 5.  The blood-brain barrier: its influence in the treatment of brain tumors metastases.

Authors:  D Fortin
Journal:  Curr Cancer Drug Targets       Date:  2012-03       Impact factor: 3.428

6.  (18)F Sodium Fluoride PET/CT in Patients with Prostate Cancer: Quantification of Normal Tissues, Benign Degenerative Lesions, and Malignant Lesions.

Authors:  Jorge D Oldan; A Stewart Hawkins; Bennett B Chin
Journal:  World J Nucl Med       Date:  2016 May-Aug

7.  The role of 18F-NaF PET/CT in metastatic bone disease.

Authors:  Mine Araz; Gülseren Aras; Özlem N Küçük
Journal:  J Bone Oncol       Date:  2015-09-16       Impact factor: 4.072

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.